Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.St Jude Medical announces Japanese approval of Durata defibrillation lead
The company said that the Durata lead incorporates a soft silicone tip with a larger surface area and a slightly curved right ventricle shock coil intended to enhance
The company said that the Durata lead incorporates a soft silicone tip with a larger surface area and a slightly curved right ventricle shock coil intended to enhance
Ethicon Endo-Surgery said that the acquisition will provide the company with a new energy platform, which complements its Harmonic line of ultrasonic medical devices that have been used
NeoGenomics will support Gene Express in its FDA validation of its lung cancer risk prediction and BCR/ABL tests. The agreements will also allow NeoGenomics to commercialize Gene Express
According to Reliant, the agreement, which is at an initial R&D stage, will combine Reliant’s expertise in developing skin rejuvenation laser treatments with Philips’s design, marketing and global
According to the company, Cleanse and Treat is the first prescription acne medication with a two-sided pad system. One side of the pad contains a leave-on cleanser (salicylic
Mr Gleeson joined The Quigley Corporation in 1998 and has served in management positions including corporate controller of the company since 2004. Mr Gleeson’s career includes his tenure
Merck has informed the company that, in light of results reported in a recently published study comparing laser treatment and intravitreal injections of triamcinolone acetonide in patients with
The recalled patches are from lot number 92461850, have expiration dates of August 31, 2009 and were manufactured by Watson Laboratories. The affected lot of fentanyl transdermal system
Leti Laboratories will provide product support and product packaging control, coordinate sales to other European distributors, distribute the company’s products in Spain and Portugal, act as the registered
The application, filed by Centocor late in 2007, seeks approval to market ustekinumab for the treatment of adult patients with chronic moderate to severe plaque psoriasis. The FDA